Zevra Therapeutics (NASDAQ:ZVRA) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Zevra Therapeutics (NASDAQ:ZVRA) from a buy rating to a hold rating in a research report sent to investors on Saturday morning.

A number of other analysts have also issued reports on ZVRA. Weiss Ratings raised shares of Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a research note on Tuesday, March 10th. HC Wainwright set a $26.00 price objective on shares of Zevra Therapeutics in a report on Tuesday, December 30th. Finally, Guggenheim set a $23.00 price objective on shares of Zevra Therapeutics and gave the company a “buy” rating in a research report on Tuesday, March 10th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $23.00.

Zevra Therapeutics Price Performance

ZVRA opened at $9.87 on Friday. The business has a fifty day moving average of $8.96 and a 200 day moving average of $9.10. The stock has a market cap of $579.47 million, a P/E ratio of 7.42 and a beta of 0.91. The company has a quick ratio of 5.63, a current ratio of 5.68 and a debt-to-equity ratio of 0.40. Zevra Therapeutics has a 52-week low of $6.19 and a 52-week high of $13.16.

Insider Transactions at Zevra Therapeutics

In other news, CEO Neil F. Mcfarlane sold 91,000 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $9.38, for a total transaction of $853,580.00. Following the transaction, the chief executive officer owned 364,350 shares of the company’s stock, valued at approximately $3,417,603. This represents a 19.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Timothy J. Sangiovanni sold 3,000 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $9.18, for a total value of $27,540.00. Following the transaction, the senior vice president owned 29,590 shares in the company, valued at approximately $271,636.20. This represents a 9.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 114,158 shares of company stock worth $1,062,878 over the last quarter. 2.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zevra Therapeutics

Several large investors have recently modified their holdings of the business. CWM LLC boosted its stake in shares of Zevra Therapeutics by 399.5% during the third quarter. CWM LLC now owns 2,872 shares of the company’s stock valued at $27,000 after purchasing an additional 2,297 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in Zevra Therapeutics by 30.0% during the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock valued at $49,000 after buying an additional 1,280 shares during the period. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in Zevra Therapeutics in the fourth quarter worth approximately $53,000. Russell Investments Group Ltd. boosted its position in Zevra Therapeutics by 235.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after acquiring an additional 4,475 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in Zevra Therapeutics by 617.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after acquiring an additional 8,552 shares in the last quarter. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.